Trial-by-gene · FLT3
Active clinical trials enrolling FLT3-mutant AML
Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.
FLT3-mutant AML trials focus on (1) gilteritinib + venetoclax + azacitidine combinations in low-intensity 1L, (2) quizartinib expansion beyond ITD into TKD, (3) post-allo SCT maintenance optimization (MORPHO follow-on), and (4) novel FLT3 inhibitors targeting F691L gatekeeper resistance.
See the FLT3 AML cheat sheet.
Browse the live listing
Search ClinicalTrials.gov for actively recruiting AML trials with FLT3-directed interventions.
Open ClinicalTrials.gov listingSource: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.
Representative trial phases and designs
Phase III, 1L low-intensity
Gilteritinib + venetoclax + azacitidine vs venetoclax + azacitidine in newly diagnosed FLT3-mutant AML, chemo-ineligible.
Phase III, post-SCT maintenance
Gilteritinib post-allo SCT maintenance in FLT3-ITD AML (MORPHO follow-on).
Phase I, next-gen FLT3 inhibitors
FF-10101 and other agents covering F691L gatekeeper resistance.
Frequently asked questions
- Are ITD-specific trials open to TKD patients?
- Many are not; quizartinib trials in particular often specify ITD. Gilteritinib and midostaurin trials are typically broader.